Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07230288 · ClinicalTrials.gov registry record · Phase 2

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
165
Enrollment target
3
Study locations

NCT07230288: Recruiting Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by AbbVie.

NCT07230288 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by AbbVie. The registered enrollment target is 165 participants, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07230288, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
165 participants
Enrollment target
3
Study locations

Study Summary

Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1). ABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is "double-blind", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world. Participants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Primary Outcome

FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

Conditions Studied

Idiopathic Pulmonary Fibrosis

Interventions

  • DRUG ABBV-142
  • DRUG Placebo for ABBV-142

Study Locations (3)

Alabama

  • Sec Clinical Research - East - Dothan - Graceland /ID# 278328 - Dothan

Illinois

  • Christie Clinic on University /ID# 277871 - Champaign

Other

  • China Medical University Hospital /ID# 278039 - Taichung

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2026-01-23
Est. Completion 2029-09
Phase Phase 2
AbbVie

526 total trials

What NCT07230288 shows while recruiting

NCT07230288 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which ABBV-142 is the first listed.

NCT07230288 reports a single indexed study location in Alabama, Illinois, Other.

Frequently Asked Questions

What is clinical trial NCT07230288 about?

NCT07230288 is a clinical study titled "Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis". Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatmen...

What is the current status of trial NCT07230288?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2026-01-23. Estimated completion is 2029-09.

What conditions does trial NCT07230288 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.

What interventions are being tested in trial NCT07230288?

The interventions under investigation include: ABBV-142 (DRUG), Placebo for ABBV-142 (DRUG).

Who is sponsoring clinical trial NCT07230288?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07230288 being conducted?

This trial has 3 study locations across Alabama, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07230288's enrollment target sits among peer trials

165 16th of 51 higher than 36 of 51 other Idiopathic Pulmonary Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02387255 · 165 participants

    Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

  • NCT03351348 · 165 participants · Phase 3

    Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

  • NCT03830320 · 165 participants · Phase 1

    Positron Emission Tomography (PET) Imaging of Thrombosis

  • NCT04289571 · 165 participants · Phase 1

    Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07230288

Source: ClinicalTrials.gov NCT07230288, the US trial registry maintained by the National Library of Medicine. NCT07230288 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.